Tuesday, August 17, 2010
Barron Report: Natural Alternative for Relief of Chronic Joint Pain and Inflammation
Shattering the false philosophy and junk science of conventional medicine
Have you ever wondered why pharmaceuticals don't work? By that, I mean that they don't make people healthier. Sure, some pharmaceuticals can modify a measurable chemical marker, but they don't make people healthier. We have 40 percent of the U.S. population on at least one prescription drug, yet our nation shows skyrocketing rates of all sorts of chronic diseases, like cancer, heart disease, type 2 diabetes, Alzheimer's disease and osteoporosis. If pharmaceuticals work to make people healthier, we should be the healthiest nation on the planet. We have people here taking more drugs than any other nation in the world. The older you get in this society, the more drugs you end up taking. Many of our senior citizens are on a dozenprescriptions a day, and half of those are usually prescribed to cover up symptoms and side effects from the first few prescriptions.
Monday, August 16, 2010
New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.
Fractures significantly reduce quality of life in postmenopausal women
(PhysOrg.com) -- Two in five women over 50 will suffer a fracture of the hip, spine or wrist that will lead to increased risk of chronic pain, reduced mobility, loss of independence and, in some cases, death.
Sunday, August 15, 2010
Osteoporosis fractures significantly reduce quality of life
Women who suffer fractures from osteoporosis experience a significant reduction in their quality of life similar to or worse than that of patients with diabetes, arthritis, lung disease and other chronic illnesses.
Report: ethical, scientific issues related to 'post-market' clinical trials
Amid growing concerns about clinical trials for drugs that have been approved by the F.D.A. but are later linked to serious health risks, an independent committee at the Institute of Medicine led by two professors from Johns Hopkins University has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.